Cell and gene therapy involves extracting cells, protein or genetic material from a patient or donor and altering them to provide a highly personalised therapy. These therapies have shown potential to offer longer-lasting effects than traditional methods.
In this talk, we will discuss the value of moving towards modular and automated, closed-system technologies designed to enable scalable and cost-effective manufacturing. Also learn more about how ViaCyte, a clinical stage regenerative medicine company, is focused on delivering novel stem cell-derived pancreatic cell replacement therapies as a functional cure for diabetes. Producing the stem cells required to support development of these therapies and future commercial demand requires an aggressive scale-up effort.
Watch this webinar to learn about:- The current challenges in cell therapy manufacturing
- How the Gibco CTS Rotea system utilizes the proven counterflow centrifugation method to enable exceptional performance for cell therapy development
- How the Rotea system is processing stem cell aggregates in bioreactors as part of a cell therapy scale-up effort
